NEURO-ENDOVASCULAR ULTRASOUND THROMBOLYSIS
UCLA Technology Available For Licensing

Stroke is the most common life-threatening neurologic disease and is the leading cause of death in the United States, after heart disease and cancer. Among the current U.S. population, some 11 million people have or will have brain aneurysms, which constitute the main cause of non-traumatic subarachnoid hemorrhage.

Stroke is defined as the acute brain injury resulting from compromised cerebral blood flow or rupture of cerebral blood vessel. Cerebral thromboembolic event occurs when blood clots occlude a branch of the cerebral arteries. When it is not treated in a timely fashion, stroke can cause permanent neurological impairments and death.

The current method of reestablishing blood flow in the blocked arteries involves the use of either systemic or local intra-arterial fibrinolytic therapy. Although there are many reports of successful recanalizations, these methods are not ideal.

Researchers at UCLA have developed a new method of treating stroke using ultrasonic energy. There are several advantages of this method over conventional fibrinolytic therapy: (1) ultrasound can recanalize arteries much quicker that fibrinolytic therapy, (2) ultrasound does not cause bleeding complications, and (3) ultrasound can be more economical that fibrinolytic therapy in itself and in overall hospital costs.

Reference: UCLA Case No. 1995-593 US Patent Number: 6,024,718

For additional technical details and current licensing
availability, please contact the following UCLA office:

UCLA Office of Intellectual Property
11000 Kinross Avenue, Suite #200
Los Angeles, CA 90095-7231
Tel: 310-794-0558 Fax: 310-794-0638
email: ncd@research.ucla.edu
Lead Inventor: Hank Chen

UCLA Technologies Available for Licensing
http://www.research.ucla.edu/tech

Copyright © 2000 The Regents of the University of California.

keywords: therapeutics medical devices uclancd ucla technologies intellectual property patents technology transfer invention business card